205 results on '"Svarovskaia, Evguenia S."'
Search Results
2. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study
3. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies
4. HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients
5. Y586F Mutation in Murine Leukemia Virus Reverse Transcriptase Decreases Fidelity of DNA Synthesis in Regions Associated with Adenine-Thymine Tracts
6. Dynamic Copy Choice: Steady State between Murine Leukemia Virus Polymerase and Polymerase-Dependent RNase H Activity Determines Frequency of in vivo Template Switching
7. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
8. Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
9. Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H
10. Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates
11. No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment
12. Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection
13. Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic Failure
14. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
15. Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and -2 Trials: 195
16. L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions: 43
17. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF
18. TOP-103 - HDV full genome sequencing and sensitive HBV genotyping from a large cohort of HBV/HDV co-infected patients
19. Persistence of Resistance-Associated Mutations after 3 Days Monotherapy with NS3 Protease Inhibitor GS-9451 in Genotype 1 HCV Patients: 804
20. Comprehensive Resistance Testing in Patients Who Relapsed after Treatment with Sofosbuvir (GS-7977)-Containing Regimens in Phase 2 Studies: 753
21. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure
22. Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis
23. No Resistance to Tenofovir Disoproxil Fumarate Detected After up to 144 Weeks of Therapy in Patients Monoinfected With Chronic Hepatitis B VirusΔ
24. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy
25. Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing
26. Correction for Han et al., “ In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir”
27. A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads
28. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects
29. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
30. Author response: Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
31. SAT-169-Prevalence of resistance associated substitutions and phylogeographic analysis of HCV infection in Russia
32. PS-150-Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA
33. SAT-168-HBV splice DNA forms detected in serum in majority of patients with chronic HBV infection
34. In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir
35. Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification
36. Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes
37. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
38. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
39. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
40. The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
41. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
42. Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir
43. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies
44. In vitro Selection of Resistance to Sofosbuvir in HCV Replicons of Genotype-1 to -6
45. Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
46. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
47. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6
48. Ledipasvir and sofosbuvir for HCV-infection in patients coinfected with HBV
49. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions
50. Relationship between Minority NNRTI Resistance Mutations, Adherence, and the Risk of Virologic Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.